Category Archives: Business of Biotech

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Biopharma Industry Enthusiastic About 2012

Eric Langer

By Eric S. Langer, president and managing partner, BioPlan Associates, Inc. 2012 Annual Study shows budgets, optimism taking a big jump It looks like the biopharma industry is actually weathering the economic downturn quite comfortably. This year we’ve surveyed hundreds of biomanufacturers and suppliers, and the industry is expressing more raw optimism and confidence than at any time in the past 9 years we’ve been surveying this industry. More Spending What this means is that wallets Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Illinois Sees Biotech as Key to Job Growth

lab

For every job created in the biotech industry, up to five additional jobs are created to build research facilities; maintain laboratory and computer equipment; supply laboratory and office equipment, and provide basic services to even the most modest biotechnology facilities. David Miller of the Illinois Biotechnology Industry Organization is well aware of the above statistic. He shared his views on the challenges and payoffs tied to establishing Chicago as a high-tech employment hub earlier this Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Drug Discovery & Development: Partnering for Success…and Survival

There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular. Partnering activity at BIO events is on Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

15 Keys to Success from Fierce Biotech’s Top 15 Women in Biotech

lab_tech

This week, Fierce Biotech recognized 15 women who are leading the way in biotech. Each of them represents the drive and determination that it takes to succeed in the industry, but what do they recommend beyond these inherent qualities? We pulled together the list below based on their profiles so that others can learn from their experience (yes, that made the list). In no particular order: 1. Take risks 2. Have an entrepreneurial spirit 3. Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: ,